---
stable_id: R-HSA-9665121
display_name: ERBB2 KD mutants bind TKIs
species: Homo sapiens
summary: 'Sensitivity to different tyrosine kinase inhibitors varies among ERBB2 mutants.
  <br><br>The following ERBB2 KD mutants are at least partially sensitive to lapatinib:<br>ERBB2
  L755M (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 D769H (Bose et al. 2013,
  Nagano et al. 2018);<br>ERBB2 V777L (Kancha et al. 2011, Bose et al. 2013, Nagano
  et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018);<br>ERBB2 T862A (Kancha et al.
  2011 - partial sensitivity, Nagano et al. 2018 - partial sensitivity);<br>ERBB2
  H878Y (Kancha et al. 2011, Nagano et al. 2018);<br><br>The following ERBB2 KD mutants
  are at least partially sensitive to neratinib (HKI-272):<br>ERBB2 L755M (Nagano
  et al. 2018);<br>ERBB2 L755P (Nagano et al. 2018 - partial sensitivity);<br>ERBB2
  L755S (Cocco et al. 2018; Nagano et al. 2018 - partial sensitivity);<br>ERBB2 I767M
  (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 D769H (Bose et al. 2013, Nagano
  et al. 2018);<br>ERBB2 D769Y (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 V777L
  (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018);<br>ERBB2
  G778_P780dup (Bose et al. 2013, Nagano et al. 2018, Ogoshi et al. 2018);<br>ERBB2
  V842I (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 T862A (Nagano et al. 2018);<br>ERBB2
  L869R (Hanker et al. 2017);<br>ERBB2 H878Y (Hu, Hu et al. 2015, Hu, Wan et al. 2015,
  Nagano et al. 2018);<br>ERBB2 R896C (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2
  L755_T759del (Bose et al. 2013);<br>ERBB2 Y772_A775dup (Minami et al. 2007)<br><br>The
  following ERBB2 KD mutants are at least partially sensitive to osimertinib: <br>ERBB2
  L755M (Nagano et al. 2018);<br>ERBB2 L755P (Nagano et al. 2018);<br>ERBB2 L755S
  (Nagano et al. 2018);<br>ERBB2 I767M (Nagano et al. 2018);<br>ERBB2 D769H (Nagano
  et al. 2018);<br>ERBB2 D769Y (Nagano et al. 2018);<br>ERBB2 V777L (Nagano et al.
  2018);<br>ERBB2 V777M (Nagano et al. 2018);<br>ERBB2 G778_P780dup (Nagano et al.
  2018 - partial response);<br>ERBB2 V842I (Nagano et al. 2018);<br>ERBB2 T862A (Nagano
  et al. 2018);<br>ERBB2 H878Y (Nagano et al. 2018);<br>ERBB2 R896C (Nagano et al.
  2018);<br><br>The following ERBB2 KD mutants are at least partially sensitive to
  afatinib (BIBW2992):<br>ERBB2 L755M (Nagano et al. 2018);<br>ERBB2 L755P (Nagano
  et al. 2018 - partial sensitivity);<br>ERBB2 L755S (Nagano et al. 2018 - partial
  sensitivity);<br>ERBB2 D769H (Nagano et al. 2018);<br>ERBB2 D769Y (Nagano et al.
  2018);<br>ERBB2 V777L (Nagano et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018);<br>ERBB2
  G778_P780dup (Suzawa et al. 2016, Nagano et al. 2018)<br>ERBB2 T798I (Hanker et
  al. 2017);<br>ERBB2 V842I (Nagano et al. 2018);<br>ERBB2 T862A (Nagano et al. 2018);<br>ERBB2
  L869R (Hanker et al. 2017);<br>ERBB2 H878Y (Hu, Wan et al. 2015, Nagano et al. 2018);<br>ERBB2
  R896C (Nagano et al. 2018);<br><br>The following ERBB2 KD mutants are at least partially
  sensitive to AZ5104:<br>ERBB2 T798I (Hanker et al. 2017);<br>ERBB2 T798M (Hanker
  et al. 2017 – partial sensitivity);<br>ERBB2 L869R (Hanker et al. 2017);<br><br>The
  following ERBB2 KD mutants are at least partially sensitive to tesevatinib (EXEL-7647):<br>ERBB2
  L755S (Trowe et al. 2008);<br>ERBB2 T798I (Trowe et al. 2008);<br><br>The following
  ERBB2 KD mutants are at least partially sensitive to canertinib (CI-1033):<br>ERBB2
  H878Y (Hu, Wan et al. 2015);<br><br>The following ERBB2 KD mutants are at least
  partially sensitive to sapitinib:<br>ERBB2 L755M (Nagano et al. 2018 - partial sensitivity);<br>ERBB2
  L755P (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 L755S (Nagano et al.
  2018 - partial sensitivity);<br>ERBB2 I767M (Nagano et al. 2018 - partial response);<br>ERBB2
  D769H (Nagano et al. 2018);<br>ERBB2 D769Y (Nagano et al. 2018);<br>ERBB2 V777L
  (Nagano et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018 - partial response);<br>ERBB2
  G778_P780dup (Nagano et al. 2018);<br>ERBB2 V842I (Nagano et al. 2018 - partial
  response);<br>ERBB2 H878Y (Nagano et al. 2018 - partial sensitivity)<br>ERBB2 R896C
  (Nagano et al. 2018   partial sensitivity);<br><br>The following ERBB2 KD mutants
  are at least partially sensitive to CP-724714:<br>ERBB2 H878Y (Hu, Wan et al. 2015);<br><br>The
  following ERBB2 KD mutants are at least partially sensitive to AEE788:<br>ERBB2
  H878Y (Kancha et al. 2011; Hu, Wan et al. 2015);<br><br>The following ERBB2 KD mutants
  are at least partially sensitive to gefitinib<br>ERBB2 L755_T759del (Bose et al.
  2013);'
---

# ERBB2 KD mutants bind TKIs
**Reactome ID:** [R-HSA-9665121](https://reactome.org/content/detail/R-HSA-9665121)
**Species:** Homo sapiens

## Summary

Sensitivity to different tyrosine kinase inhibitors varies among ERBB2 mutants. <br><br>The following ERBB2 KD mutants are at least partially sensitive to lapatinib:<br>ERBB2 L755M (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 D769H (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 V777L (Kancha et al. 2011, Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018);<br>ERBB2 T862A (Kancha et al. 2011 - partial sensitivity, Nagano et al. 2018 - partial sensitivity);<br>ERBB2 H878Y (Kancha et al. 2011, Nagano et al. 2018);<br><br>The following ERBB2 KD mutants are at least partially sensitive to neratinib (HKI-272):<br>ERBB2 L755M (Nagano et al. 2018);<br>ERBB2 L755P (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 L755S (Cocco et al. 2018; Nagano et al. 2018 - partial sensitivity);<br>ERBB2 I767M (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 D769H (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 D769Y (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 V777L (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018);<br>ERBB2 G778_P780dup (Bose et al. 2013, Nagano et al. 2018, Ogoshi et al. 2018);<br>ERBB2 V842I (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 T862A (Nagano et al. 2018);<br>ERBB2 L869R (Hanker et al. 2017);<br>ERBB2 H878Y (Hu, Hu et al. 2015, Hu, Wan et al. 2015, Nagano et al. 2018);<br>ERBB2 R896C (Bose et al. 2013, Nagano et al. 2018);<br>ERBB2 L755_T759del (Bose et al. 2013);<br>ERBB2 Y772_A775dup (Minami et al. 2007)<br><br>The following ERBB2 KD mutants are at least partially sensitive to osimertinib: <br>ERBB2 L755M (Nagano et al. 2018);<br>ERBB2 L755P (Nagano et al. 2018);<br>ERBB2 L755S (Nagano et al. 2018);<br>ERBB2 I767M (Nagano et al. 2018);<br>ERBB2 D769H (Nagano et al. 2018);<br>ERBB2 D769Y (Nagano et al. 2018);<br>ERBB2 V777L (Nagano et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018);<br>ERBB2 G778_P780dup (Nagano et al. 2018 - partial response);<br>ERBB2 V842I (Nagano et al. 2018);<br>ERBB2 T862A (Nagano et al. 2018);<br>ERBB2 H878Y (Nagano et al. 2018);<br>ERBB2 R896C (Nagano et al. 2018);<br><br>The following ERBB2 KD mutants are at least partially sensitive to afatinib (BIBW2992):<br>ERBB2 L755M (Nagano et al. 2018);<br>ERBB2 L755P (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 L755S (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 D769H (Nagano et al. 2018);<br>ERBB2 D769Y (Nagano et al. 2018);<br>ERBB2 V777L (Nagano et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018);<br>ERBB2 G778_P780dup (Suzawa et al. 2016, Nagano et al. 2018)<br>ERBB2 T798I (Hanker et al. 2017);<br>ERBB2 V842I (Nagano et al. 2018);<br>ERBB2 T862A (Nagano et al. 2018);<br>ERBB2 L869R (Hanker et al. 2017);<br>ERBB2 H878Y (Hu, Wan et al. 2015, Nagano et al. 2018);<br>ERBB2 R896C (Nagano et al. 2018);<br><br>The following ERBB2 KD mutants are at least partially sensitive to AZ5104:<br>ERBB2 T798I (Hanker et al. 2017);<br>ERBB2 T798M (Hanker et al. 2017 – partial sensitivity);<br>ERBB2 L869R (Hanker et al. 2017);<br><br>The following ERBB2 KD mutants are at least partially sensitive to tesevatinib (EXEL-7647):<br>ERBB2 L755S (Trowe et al. 2008);<br>ERBB2 T798I (Trowe et al. 2008);<br><br>The following ERBB2 KD mutants are at least partially sensitive to canertinib (CI-1033):<br>ERBB2 H878Y (Hu, Wan et al. 2015);<br><br>The following ERBB2 KD mutants are at least partially sensitive to sapitinib:<br>ERBB2 L755M (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 L755P (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 L755S (Nagano et al. 2018 - partial sensitivity);<br>ERBB2 I767M (Nagano et al. 2018 - partial response);<br>ERBB2 D769H (Nagano et al. 2018);<br>ERBB2 D769Y (Nagano et al. 2018);<br>ERBB2 V777L (Nagano et al. 2018);<br>ERBB2 V777M (Nagano et al. 2018 - partial response);<br>ERBB2 G778_P780dup (Nagano et al. 2018);<br>ERBB2 V842I (Nagano et al. 2018 - partial response);<br>ERBB2 H878Y (Nagano et al. 2018 - partial sensitivity)<br>ERBB2 R896C (Nagano et al. 2018   partial sensitivity);<br><br>The following ERBB2 KD mutants are at least partially sensitive to CP-724714:<br>ERBB2 H878Y (Hu, Wan et al. 2015);<br><br>The following ERBB2 KD mutants are at least partially sensitive to AEE788:<br>ERBB2 H878Y (Kancha et al. 2011; Hu, Wan et al. 2015);<br><br>The following ERBB2 KD mutants are at least partially sensitive to gefitinib<br>ERBB2 L755_T759del (Bose et al. 2013);
